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ABSTRACT
The METTEN study assessed the efficacy, tolerability, and safety of adding 
metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive 
breast cancer (BC). Women with primary, non-metastatic HER2-positive BC were 
randomized (1:1) to receive metformin (850 mg twice-daily) for 24 weeks concurrently 
with 12 cycles of weekly paclitaxel plus trastuzumab, followed by four cycles of 
3-weekly FE75C plus trastuzumab (arm A), or equivalent regimen without metformin 
(arm B), followed by surgery. Primary endpoint was the rate of pathological complete 
response (pCR) in the per-protocol efficacy population. pCR rate was numerically 
higher in the metformin-containing arm A (19 of 29 patients [65.5%, 95% CI:  
47.3–80.1]) than in arm B (17 of 29 patients [58.6%, 95% CI: 40.7–74.5]; OR 1.34 
[95% CI: 0.46–3.89], P = 0.589). The rate of breast-conserving surgery was 79.3% 
and 58.6% in arm A and B (P = 0.089), respectively. Blood metformin concentrations 
(6.2 μmol/L, 95% CI: 3.6–8.8) were within the therapeutic range. Seventy-six 
percent of patients completed the metformin-containing regimen; 13% of patients 
in arm A dropped out because of metformin-related gastrointestinal symptoms. The 
most common adverse events (AEs) of grade ≥3 were neutropenia in both arms and 
diarrhea in arm A. None of the serious AEs was deemed to be metformin-related. 
Addition of anti-diabetic doses of metformin to a complex neoadjuvant regimen was 
well tolerated and safe. Because the study was underpowered relative to its primary 
endpoint, the efficacy data should be interpreted with caution.
INTRODUCTION
Metformin, a biguanide derivative that reduces 
insulin levels, has long been a cornerstone in the treatment 
of type 2 diabetes (T2D). There is now compelling evidence 
to incorporate metformin into the armamentarium against 
cancer, particularly breast cancer (BC). Notwithstanding 
the limitations of observational studies, many have 
consistently indicated that metformin can reduce the 
incidence, outcome, and mortality of BC in patients with 
T2D [1–3]. Moreover, preclinical studies have described a 
variety of molecular mechanisms through which metformin 
indirectly or directly inhibits the growth of BC cells in vitro 
and in vivo [4–6].
The extensive clinical experience accumulated 
from patients with T2D prescribed metformin, together 
with its well characterized and modest toxicity profile 
[7, 8], has significantly shortened the clinical evaluation 
path of metformin in cancer prevention and treatment 
[9–11]. Accordingly, many clinical studies, including 
proof-of-principle studies in the prevention setting and 
phase 2 trials in the adjuvant and metastatic settings, 
have been planned and/or are currently under way to test 
the causal nature of the suggested correlation between 
metformin and clinical benefit in cancer.
To avoid overestimation of the potential effects of 
metformin in unselected populations of nondiabetic BC 
patients, preoperative translational studies are important 
to define specific BC subgroups more likely to benefit 
from metformin-based regimens. The neoadjuvant 
(preoperative) approach is known to maximize the 
capacity to test the benefits of drug combinations in the 
context of carefully designed clinical trials of early BC 
[12–15]. In this regard, a landmark retrospective study 
revealed that patients with T2D and BC who received 
metformin and neoadjuvant chemotherapy appeared 
to have a higher pCR rate than did those not receiving 
metformin [16], a hypothesis-generating finding that 
warrants prospective evaluation. 
Metformin has been shown to suppress both the 
tyrosine kinase activity and the expression of the human 
epidermal growth factor receptor 2 (HER2) protein in 
in vitro models of HER2-overexpressing BC cells 
[17–20], in addition to prolonging survival in HER2-
overexpressing transgenic BC mouse models [21]. 
Metformin treatment leads also to lower levels of 
circulating insulin and insulin-like growth factor (IGF-I), 
and to cell-autonomous inhibition of the mTOR pathway 
[22–25]. Such a multi-faceted capacity of metformin to 
target not only HER2 itself but also central mechanisms 
implicated in refractoriness to HER2-targeted therapies 
including both the IGF-I/mTOR signaling pathway and the 
self-renewal/proliferation of tumor-initiating cancer stem 
cells [26–30] provides strong experimental support to 
translate these pre-clinical findings into new metformin-
based clinical management strategies that may benefit 
HER2-positive BC patients. However, most of the in-vitro 
models showing anti-HER2 activity of metformin used 
drug concentrations in the millimolar range, far higher 
than reported plasma metformin concentrations seen in 
diabetic patients treated with metformin [27, 31, 32], 
thereby leaving unanswered the question of whether 
metformin would have a clinical effect in patients 
suffering from HER2-positive BC. 
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The open-label, multicenter, phase II randomized 
METTEN study [33] (EudraCT number 2011-000490-
30) evaluated the clinical activity, tolerability, and safety 
of adding metformin to neoadjuvant chemotherapy 
plus trastuzumab in operable, locally advanced, or 
inflammatory HER2-positive BC. 
RESULTS
Patient characteristics and disposition
Between June 1, 2012 and March 17, 2016, 98 
patients at 10 centers in Spain were recruited into the 
METTEN study. Due to slow accrual, the study closed 
prematurely with a reduced sample size after 84 of 244 
planned patients were randomly assigned: 41 enrolled 
patients were allocated to the metformin group (arm A) 
and 43 patients to the non-metformin group (arm B). 
Figure 1 shows the CONSORT diagram 
summarizing disposition of patients. Fourteen patients did 
not meet inclusion criteria and were not enrolled at the 
time of randomization. Nine patients in arm A and four 
patients in arm B failed to receive their allocated treatment, 
either due to treatment-related toxicity (eight patients in 
arm A and three in arm B) or they refused further follow-
up or treatment (one in each arm) (Supplementary Table 2). 
Five patients were excluded from safety analyses because 
of informed consent withdrawal (two patients in arm A, 
one patient in arm B) or major protocol violation (one 
in each arm). The trial profile and treatment schedule is 
shown in Figure 2.
Patients and tumor characteristics of the modified 
ITT (mITT) population are summarized in Table 1. 
The baseline characteristics of the PP population 
(Supplementary Table 1) were similar to those of the mITT 
population. Most patients had T2 tumors (66% and 59% in 
arms A and B, respectively) and lymph node involvement 
(72% in arms A and B) at diagnosis. Within each stratum, 
no imbalances in terms of patient characteristics were 
observed across the two arms. Patients were stratified by 
age, extent of disease, and HR status. 
Responses and surgery
The primary endpoint was the rate of pCR in 
breast and axilla in the efficacy analyzable PP population 
(twenty-nine patients in each arm). In arm A, 19/29 PP 
patients (65.5%, 95% CI: 47.3–80.1%) had a pCR versus 
17/29 PP patients (58.6%, 95% CI: 40.7–74.5%) in arm B. 
The minimum clinically important difference that could 
be detectable considering the available PP population 
size (27.7%; α = 0.15, β = 0.20) was included in the upper 
limit (31.8%) of the confidence interval of the difference 
of pCR rates between the metformin-containing and 
the standard reference arm. The combined rates of pCR 
(ypT0/is, ypN0) and near-pCR, the latter defined as 
presence of infiltrating residual disease of less than 5 mm 
and node negativity (ypT1aN0), were 79.3% (95% CI: 
61.6–90.2%) in arm A and 72.4% (95% CI: 54.3–85.3%) 
in arm B (Table 2). 
Breast-conserving surgery (BCS) was possible in 
79.3% of patients in arm A, which was apparently superior 
to the 58.6% achieved in arm B (P = 0.089, Table 2). 
Among patients undergoing BCS, 91.3% achieved a 
pCR/near pCR in the metformin arm versus 76.5% in the 
reference arm (Table 2).
Supplementary Table 3 summarizes the pCR and 
surgery analyses performed for the mITT population. In 
Arm A, 19/38 mITT patients (50%, 95% CI: 34.8–65.1%) 
had a pCR versus 23/41 mITT patients (56.1%, 95% CI: 
41.0–70.1%) in arm B. BCS was possible in 78.4% of 
mITT patients in arm A, which was superior to the 61.0% 
achieved in arm B (P = 0.096). 
Prediction of response
Although the study was underpowered (42%) 
because of a small number of patients evaluable for the 
primary endpoint, we performed an exploratory analysis 
to describe the distribution of pCR rates between arms in 
the analyzable PP efficacy population. Such exploratory 
analysis showed no differences between the two arms 
(odds ratio [OR] 1.34 [95% CI: 0.46–3.89], P = 0.589; 
Table 3). The analysis performed in the mITT population 
similarly showed no differences between the two arms 
(OR 0.78 [95% CI: 0.32–1.90], P = 0.588; Supplementary 
Table 4).
In univariable analysis for predetermined factors 
predicting a pCR in the two arms, solely T2 and PgR 
negativity (P = 0.021) appeared to associate with the 
probability of achieving pCR (OR 3.12 [95% CI: 1.02–
9.48] and 3.76 [95% CI: 1.23–11.51], respectively) in the 
efficacy analyzable PP population (Table 3). In bivariate 
analysis, PgR negativity seemed to show predictive 
capacity irrespective of the arm in which the patients 
were randomized (Supplementary Table 5). In the mITT 
population, a similar association appeared to occur 
between PgR negativity and the probability of achieving 
pCR in uni- and bivariate analysis (Supplementary Tables 
4 and 6, respectively). 
In multivariable analysis, PgR negativity no longer 
associated with the probability of achieving a pCR (data 
not shown). Supplementary Tables 7 and 8 summarizes 
how the pCR rates in both arms appeared to remain 
unchanged according to hormonal receptor status in the 
PP and mITT populations, respectively.
Circulating metformin
We assessed serum concentrations of metformin in a 
subgroup of twenty-two patients using HPLC-ESI-QTOF-MS 
(Figure 3). Inadequate blood samples were drawn in 
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two patients and were excluded from the analysis. The 
mean concentration was determined to be 6.2 μmol/L 
(95% CI: 3.6–8.8) with a range from 0.1 μmol/L to 
21.1 μmol/L. We detected slightly higher levels of 
circulating metformin in patients achieving pCR (mean 
7.1 μmol/L; 95% CI: 3.0–11.1) than in those belonging to the 
non-responders group (mean 4.7 μmol/L; 95% CI: 2.7–6.7; 
P = 0.757). Supplementary Figure 1 shows the distribution 
of serum metformin through concentrations as a function of 
the time of blood sampling/metformin intake. 
Compliance with treatment and toxicity
The most frequently occurring AEs (290 in arm A 
and 306 in arm B) were fatigue, diarrhea, nausea, alopecia, 
sensory neuropathy, mucositis, neutropenia, and elevated 
AST/ALT (Table 4, Supplementary Table 9). Most AEs 
were of grades 1 and 2 (92.1% in arm A and 95.8% in 
arm B; Table 4, Supplementary Table 9). The majority of 
the most frequent AEs were deemed possibly related to 
study treatment. The overall incidence of AEs of grade 
≥3 ranged from 7.9% (23/290 events) in arm A to 4.3% 
(13/306 events) in arm B; the most common of which were 
neutropenia (7/38 patients in arm A and 5/41 patients in 
arm B) and diarrhea (5 and 0, respectively; Table 4).
The number of serious AEs requiring hospitalization 
was three in arm A and two in arm B (details are 
summarized in the Supplementary Table 10). No 
treatment-related deaths occurred.
Cardiac tolerability
Table 5 shows baseline LVEF values and changes 
during neoadjuvant treatment in the two study arms. 
LVEF dropped below baseline during the treatment period 
in both arms; however, mean and median decreases were 
no more than 5% (Supplementary Table 11). Although the 
profiles of LVEF changes over time were similar between 
arms (Figure 4), only one (2.9%) patient in arm A and six 
(15%) in arm B exhibited asymptomatic decreases in LVEF 
below the institutional lower limit (50%) and >10% from 
baseline at week 12 (P = 0.032; Table 5). At the treatment 
end, none (0%) of the patients in arm A and three (8.1%) in 
arm B presented decreases in LVEF (P = 0.409; Table 5). 
Only one patient (2.7%) in arm B experienced symptomatic 
heart failure.




The METTEN study compared conventional 
chemotherapy plus trastuzumab with the combination 
of metformin and chemotherapy plus trastuzumab in the 
neoadjuvant setting for treatment of early HER2-positive 
BC. 
Assessment of pCR using the definition ypT0/
is, ypN0 showed that the two treatment regimens were 
highly active, with pCR rates ranging from 58.6% in 
the reference arm to 65.5% in the metformin arm. Such 
high pCR rates in the small sample size of the METTEN 
study were consistent with those originally reported in 
the MD Anderson Cancer Center trial (55–65%) [34, 35] 
and with our previous experience (61.4%) of concurrent 
trastuzumab plus weekly paclitaxel-FEC as primary 
therapy for HER2-positive BC in everyday clinical 
practice [36]. Although the pCR rates in our study were 
numerically higher than those generally found in larger 
randomized phase III trials such as the NOAH [37], the 
GeparQuattro [38], the HannaH [39], or the Cortazar meta-
analysis of neoadjuvant BC trials [13], which reported 
pCR rates up to 40%, such differences were most likely 
due to differences in study populations. 
The numerically higher pCR rate observed in the 
PP population receiving the neoadjuvant metformin did 
not reach statistical significance in our study. However, 
it should be acknowledged that the trial was closed 
before the first scheduled interim analysis due to slow 
recruitment. As a result, a formal statistical comparison 
of treatment arms in the reported efficacy/PP population 
was statistically underpowered, and the efficacy analysis 
should be considered purely exploratory. Evaluation 
of long-term outcome data such as 5-year DFS together 
with correlative biological studies evaluating proliferation 
markers (e.g., Ki-67) and selected predictive factors of 
response to neoadjuvant treatment in HER2-positive BC 
(e.g., EGFR and PTEN) are currently underway in our 
laboratory to adequately appraise whether those patients who 
received neoadjuvant metformin might gain an additional 
survival benefit and the mechanisms involved [35, 40–44]. 
Although a higher BCS rate was observed in patients 
receiving additional metformin, breast conservation is known 
to depend on multiple parameters including breast size, tumor 
location, presence of DCIS, the multifocality of the lesion, 
or patient willingness [45], thus making it challenging to 
attribute such differences to a true clinico-molecular benefit 
in those patients receiving neoadjuvant metformin. 
Figure 2: METTEN study design. Stratification factors: age, extent of disease (cT2 cN0-1 vs ≥ cT3 or ≥ cN2), and hormone receptor 
(HR) status. Primary endpoint: pCR in breast and axilla. (HER2, human epidermal growth factor receptor; LVEF, left ventricular ejection 
fraction; pCR, pathological complete response). 
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Table 1: Baseline patient demographic and tumor characteristics for the mITT population
  Arm A (N = 38) Arm B (N = 41) P value
Age (years) 0.780
<50 22 (57.9%) 25 (61.0%)
≥50 16 (42.1%) 16 (39.0%)
Mean ± SD (range) 47.2 ± 10.6 (26–75) 48.0 ± 11.5 (23–72) 0.754
Menopausal status 0.818
Post 14 (36.8%) 17 (41.5%)
Pre 24 (63.2%) 24 (58.8%)
Body weight (kg)
Mean ± SD (range) 64.6 ± 8.7 (45.3–89.0) 65.2 ± 9.4 (48.0–83.0) 0.289
Body mass index (BMI) 0.564
<25 21 (55.3%) 20 (48.8%)
≥25 (overweight) 17 (44.7%) 21 (51.2%)
Clinical tumor status 0.681
cT2 25 (65.8%) 26 (63.4%)
cT3 12 (31.6%) 10 (24.4%)
cT4a 0 (0.0%) 1 (2.4%)
cT4b 1 (2.6%) 3 (7.3%)
cT4d 0 (0.0%) 1 (2.4%)
Clinical nodal Stage 0.445
cN0 9 (23.7%) 13 (31.7%)
cN1 24 (63.2%) 20 (48.8%)
cN2 1 (2.6%) 4 (9.7%)
cN3 4 (10.5%) 4 (9.7%)
Hormone receptor status 0.477
  ER and/or PgR positive 19 (50.0%) 24 (58.5%)
  ER and PR negative 19 (50.0%) 17 (41.5%)
Tumor grade 0.272
G1 2 (7.1%) 0 (0.0%)
G2 12 (42.9%) 18 (54.5%)
G3 14 (50.0%) 15 (45.5%)
Unknown 10 8
Baseline LVEF (%) 0.755
[50–55] 3 (10.3%) 2 (6.3%)
[55–60] 7 (24.1%) 6 (18.8%)
[60–65] 8 (27.6%) 13 (40.6%)
[65–70] 11 (37.9%) 11 (34.4%)
≥70 9 9
Type of programmed surgery 0.171
 Breast-conserving 26 (76.5%) 24 (61.5%)
 Mastectomy 8 (23.5%) 15 (38.5%)
 Unknown 4 2
LVEF: Left Ventricular Ejection Fraction.
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Data from the Asian Medical Center Breast Cancer 
Database concluded that diabetic patients receiving 
metformin when BC is diagnosed show a better prognosis 
only if they had HR-positive, HER2-positive tumors [46]. 
Moreover, an analysis of the ALTTO Phase III randomized 
trial, which assigned patients with HER2-positive BC to 
receive 1 year of trastuzumab alone, lapatinib alone, their 
sequence, or their combination, found that metformin 
exerted a statistically-significant beneficial effect in those 
patients with diabetes who had primary HER2-positive 
and HR-positive BC [47]. Neoadjuvant trials with anti-
HER2 therapy have demonstrated a HR status-related 
prognostic value after achieving a pCR, with a higher 
survival effect in the HR-negative group than in the HR-
positive group [48]. In the METTEN study, a higher 
percentage of PgR-negative patients achieved a pCR in 
both arms, thus confirming the notion that the likelihood 
of response according to HR status is an intrinsic 
characteristic of HER2-positive tumors [49, 50]. However, 
we failed to clarify the actual predictive value of pCR in 
the metformin-containing arm according to HR status. 
After hepatic uptake, the plasma concentration of 
metformin is reduced to 5–20 μmol/L after oral doses of 
0.5–1.5 g metformin in humans with a mean plasma half-
life of about 20 h [6, 31, 51]. Our analytical determination of 
serum metformin confirmed that treatment of non-diabetic 
HER2+ BC patients with oral metformin (850 mg twice-
daily) for 24 weeks produced blood levels of circulating 
metformin (approx. 7 μmol/L) equivalent to those generally 
achieved in diabetic patients at the usual clinical doses 
and schedules [27, 31, 32]. Although systemic exposure 
of metformin seemed more elevated in those patients 
achieving a pCR than in non-responder patients, two 
outliers within the responder group appeared to drive such 
trend that failed to reach statistical significance. Moreover, 
we measured circulating concentrations of metformin in 
blood samples that were not strictly timed in terms of hours 
since preceding oral dose [51] and, therefore, our data need 
to be viewed cautiously in terms of any association between 
achieved serum concentration and probability of pCR. 
One major concern regarding the utility of metformin 
is its known ability to induce gastrointestinal upset 
Table 2: Surgery and pathologic response in the PP efficacy population
   Arm A (N = 29) Arm B (N = 29) P value
Type of surgery 
Mastectomy 6 (20.7%) 12 (41.4%) 0.089
Breast-conserving surgery 23 (79.3%) 17 (58.6%)
Response
pCR 0.588
No 10 (34.5%) 12 (41.4%)
Yes 19 (65.5%) 17 (58.6%)
pCR + near pCR 0.539
No 6 (20.7%) 8 (27.6%)
Yes 23 (79.3%) 21 (72.4%)
Type of surgery & response
Mastectomy (N = 18)
pCR 0.620
  No 4 (66.7%) 5 (41.7%)
  Yes 2 (33.3%) 7 (58.3%)
pCR + near pCR 0.321
  No 4 (66.7% 4 (33.3%)
  Yes 2 (33.3%) 8 (66.7%)
Breast-conserving surgery (N  = 40)
pCR 0.314
  No 6 (26.1%) 7 (41.2%)
  Yes 17 (73.9%) 10 (58.8%)
pCR + near pCR 0.373
  No 2 (8.7%) 4 (23.5%)
  Yes 21 (91.3%) 13 (76.5%)  
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and diarrhea, which might limit patient compliance, 
particularly when combined with cytotoxic chemotherapy 
[52]. The METTEN study confirms that metformin is likely 
a tolerable and safe addition to current therapy regimens 
[53, 54]. From the perspective of tolerability, it should 
be noted that the dropout rate in the metformin arm was 
much lower than the expected 25%; only 13% (5 out of 
38) of patients withdrew because of metformin-related 
gastrointestinal upset and diarrhea, whereas more than 75% 
(29 out of 38) patients completed the 6-month intervention 
with metformin as part of a complex neoadjuvant 
combination. The safety of the triple regimen of metformin, 
chemotherapy, and trastuzumab was similar to that of 
chemotherapy and trastuzumab. None of the three serious 
AEs in arm A was deemed to be exclusively metformin-
related. Because residual disease after neoadjuvant 
therapy is a poor prognostic factor [55], it would be 
relevant to evaluate whether upregulated mitochondrial 
oxidative phosphorylation (OXPHOS) –a primary target of 
metformin- is part of the metabolic shifts that drive tumor 
recurrence in residual BC [56], thereby allowing metformin 
to be considered as a safe candidate to treat OXPHOS-
dependent residual BC disease.
When we evaluated the cardiac tolerability of 
metformin given in the triple regimen, metformin did 
not increase the baseline rate of cardiac dysfunction 
observed in the reference arm. Moreover, by assessing 
the trajectories of LVEF decline over time, we observed 
a small trend towards a lower number of asymptomatic 
cardiac events in the metformin-containing arm. HER2 
signaling is involved in myocardial homeostasis and 
its inhibition may explain the increased incidence of 
cardiomyopathy associated with the treatment with 
trastuzumab, particularly in those patients exposed 
to cardiotoxic chemotherapies such as anthracyclines 
[57, 58]. Trastuzumab-induced cardiomyopathy relates, 
at least in part, to its inability to activate pro-survival 
catabolic pathways through AMP-activated protein kinase 
(AMPK) in cardiac cells [59, 60]. Because metformin 
treatment has been shown to improve cardiovascular 
function and reduce cardiovascular risk in diabetic 
patients through the activation of AMPK [61]–a cell-
autonomous mechanism that also underlies the activity of 
metformin as an anticancer drug [4–6]– larger and longer-
term studies evaluating biomarkers of cardiotoxicity in 
trastuzumab-exposed oncologic populations will be 
needed to clarify whether metformin induces AMPK 
(and downstream catabolic) signaling upon trastuzumab-
induced metabolic dysregulation in cardiomyocytes 
[20, 62].
Table 3: Univariable analysis of factors associated with a pCR in the PP efficacy population 
Category  No pCR N (%) pCR N (%) OR (95% CI) P value
Arm
B 12 (41.4%) 17 (58.6%) 1
A 10 (34.5%) 19 (65.5%) 1.34 (0.46–3.89) 0.589
Age (years)
<50 16 (47.1%) 18 (52.9%)
≥50 6 (25.0%) 18 (75.0%) 2.67 (0.85–8.37) 0.093
Clinical tumor stage
≥T3 12 (52.2%) 11 (47.8%) 1
T2 10 (28.6%) 25 (71.4%) 3.12 (1.02–9.48) 0.073
Clinical nodal status
N ≥ 2 4 (40.0%) 6 (60.0%) 1
N0–1 18 (37.5%) 30 (62.5%) 1.11 (0.28–4.48) 0.882
ER
Positive 13 (43.3%) 17 (56.7%) 1
Negative 9 (32.1%) 19 (67.9%) 1.61 (0.55–4.72) 0.381
PgR
Positive 13 (56.5%) 10 (43.5%) 1
Negative 9 (25.7%) 26 (74.3%) 3.76 (1.23–11.51) 0.021
HR status
Positive 14 (45.2%) 17 (54.8%) 1
 Negative  8 (29.6%) 19 (79.4%) 1.96 (0.66–5.80) 0.227
OR, odds ratio.
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During recruitment, the findings of the phase II 
NeoSphere [49] and TRYPHAENA trials [63], together 
with the impressive survival benefits for women with 
HER2-positive metastatic BC receiving pertuzumab along 
with trastuzumab in the phase III CLEOPATRA study [64], 
led to the accelerated approval of pertuzumab by the FDA 
in September 2013 and the European Medicines Agency 
in July 2015 for use in combination with trastuzumab plus 
chemotherapy for neoadjuvant treatment of patients with 
HER2-positive locally advanced, inflammatory, or early-
stage BC. Consequently, ethical issues arose during the 
METTEN study trial based on the recommended standard 
of care supported by national and international guidelines 
with a neoadjuvant combination of taxane-containing 
chemotherapy and a dual blockade of trastuzumab and 
pertuzumab. Moreover, we cannot exclude the possibility 
that a rejection bias might exist against the repurposing 
of generic non-cancer metformin as oncological treatment 
when confronted to commercially developed anti-cancer 
drugs [65]. 
Two previous randomized phase II trials have shown 
that metformin in combination with systemic therapy 
fails to significantly improve outcomes in patients with 
advanced/metastatic pancreatic cancer [66, 67]. These 
studies by Kordes [66] and Reni [67] intended very 
ambitious clinical targets in terms of overall survival 
(from 50% to 75% at 6 months) and progression-free 
survival (from 50% to 70% at 6 months), respectively. 
Because the METTEN trial failed to identify also a large 
difference, i.e., a 25% increase over an expected pCR 
of 60% with chemotherapy plus trastuzumab before a 
phase 3 trial could be justified, it might be tempting to 
suggest that testing against high bars of clinical outcome 
endpoints instead of using a priori non-inferiority trial 
designs should be cautiously considered before concluding 
that studies using metformin for treating cancer should be 
abandoned. Moreover, negative results of first-generation 
cancer trials using metformin at the same dose and 
route of administration that in diabetic patients would 
not rule out the clinical utility of biguanides other than 
metformin (e.g., phenformin) or non-conventional routes 
for administering biguanides if previously optimized for 
oncology indications [68–71]. However, as we did not 
achieve the target number of patients to power the study, 
we cannot be certain whether the lack of significant 
difference between the two arms of the METTEN 
trial is a type II error or reflects a true lack of efficacy 
for the metformin-based neoadjuvant strategy in early 
HER2-positive BC. Beyond general considerations such 
as the need to consolidate prognostic, predictive, and 
pharmacodynamic factors of the metabolic response to 
metformin for selecting subsets of patients most likely 
to benefit from metformin treatment, mature results from 
large, randomized studies, such as the NCIC CTG MA.32, 
the most advanced adjuvant trial investigating the effects 
of metformin versus placebo on invasive DFS and other 
Figure 3: Circulating serum metformin. Box plots indicating median (black lines within the boxes), interquartile ranges, whiskers 
and ranges for post-treatment levels of circulating serum metformin (μmol/L; N = 20). (pCR: pathological complete response). 
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Table 4: Cardiac and most common adverse events reported as possibly, probably, or definitely related to treatment 
in the mITT population
   Arm A (N = 38)  Arm B (N  = 41)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Hematological toxicity           
Anemia 3 (7.9%) 3 (7.9%) 2 (5.3%) 0 (0.0%) 2 (4.9%) 4 (9.8%) 0 (0.0%) 0 (0.0%)
Thrombocytopenia 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Leukopenia 3 (7.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (7.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Neutropenia 2 (5.3%) 4 (10.5%) 5 (13.2%) 2 (5.3%) 4 (9.8%) 2 (4.9%) 4 (9.8%) 1 (2.4%)
Febrile Neutropenia 0 (0.0%) 0 (0.0%) 1 (2.6%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%)
Gastrointestinal disorders           
Diarrhea 18 (47.4%) 5 (13.2%) 5 (13.2%) 0 (0.0%) 12 (29.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Constipation 4 (10.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Nausea 14 (36.8%) 4 (10.5%) 1 (2.6%) 0 (0.0%) 12 (29.3%) 4 (9.8%) 1 (2.4%) 0 (0.0%)
Vomiting 12 (31.6%) 5 (13.2%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 1 (2.4%) 1 (2.4%) 0 (0.0%)
Mucositis 13 (34.2%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 12 (29.3%) 5 (12.2%) 0 (0.0%) 0 (0.0%)
Dyspepsia 2 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pyrosis 3 (7.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (14.6%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Epigastric Pain 6 (15.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (12.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
General disorders           
Fatigue 22 (57.9%) 8 (21.1%) 1 (2.6%) 0 (0.0%) 23 (56.1%) 11 (26.8%) 0 (0.0%) 0 (0.0%)
Headache 2 (5.3%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Fever 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Vascular disorders           
Edema 2 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hypertension 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Skin disorders           
Alopecia 5 (13.2%) 12 (31.6) 0 (0.0%) 0 (0.0%) 9 (22.0%) 9 (22.0%) 0 (0.0%) 0 (0.0%)
Rash 7 (18.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Erythema 2 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 0 (0.0%) 1 (2.4%) 0 (0.0%)
Pruritus 4 (10.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Nail changes 3 (7.9%) 2 (5.3%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Toxicodermic reaction 
to chemotherapy 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 0 (0.0%)
Rosacea 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 0 (0.0%)
Skin toxicity 2 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (7.3%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Metabolism disorders           
Anorexia 4 (10.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Hypercalcemia 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hypercholesterolemia 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Hypertriglyceridemia 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Metabolism disorders           
AST/ALT increased 8 (21.1%) 3 (7.9%) 2 (5.3%) 0 (0.0%) 7 (17.1%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Musculoskeletal disorders           
Arthralgia 3 (7.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (14.6%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Myalgia 8 (21.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 7 (17.1%) 2 (4.9%) 0 (0.0%) 0 (0.0%)
Septic arthritis 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
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outcomes on early BC in 3,649 women [10], will be of 
great interest to confirm or reject [72] the causal nature 
of the suggested correlation between metformin use and 
survival benefit in BC patients. 
MATERIALS AND METHODS
Study design and objectives
Patients were randomly assigned to receive daily 
metformin (850 mg twice-daily) for 24 weeks concurrently 
with 12 cycles of weekly paclitaxel plus trastuzumab 
followed by four cycles of 3-weekly fluorouracil, 
epirubicin, cyclophosphamide plus trastuzumab (arm A) 
or equivalent sequential chemotherapy plus trastuzumab 
without metformin (arm B), followed by surgery. 
The primary end point was pCR, defined as 
absence of invasive tumor cells on hematoxylin and eosin 
evaluation of the complete resected breast specimen (and 
all sample regional lymph nodes if lymphadenectomy 
was performed) following the completion of neoadjuvant 
systemic therapy. Residual ductal carcinoma in situ (DCIS) 
only was included in the definition of pCR (ypT0/is, 
ypN0). Secondary aims included the tolerability and safety 
profile of the metformin-based neoadjuvant combination 
including cardiac toxicity, the rate of breast conservation, 
Nervous system disorders           
Sensory Neuropathy 10 (26.3%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 19 (46.3%) 5 (12.2%) 0 (0.0%) 0 (0.0%)
Dizziness 1 (2.6%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Dysgeusia 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (9.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Respiratory disorders           
Epistaxis 3 (7.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9 (22.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Dyspnea 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (7.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Reproductive system           
Amenorrhea 1 (2.6%) 3 (7.9%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 0 (0.0%) 0 (0.0%)
Cardiac disorders           
Left ventricular 
systolic dysfunction 0 (0.0%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 1 (2.4%) 0 (0.0%)
 Dilated aortic root  1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)  0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Data are N (%).
Figure 4: Left ventricular ejection fraction (LVEF) per treatment arm. Box plots indicating median (black lines within the 
boxes), interquartile ranges, whiskers and ranges for LVEF at baseline, after 12–13 weeks, and at the end of therapy. 
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5-year disease-free survival (DFS), the inhibition of tumor 
tissue biomarkers (including proliferative, mTOR/AMPK- 
and HER2-related pathways), and changes in circulating 
levels of insulin and metabolites. Studies of disease free 
survival rates and correlative biological markers are 
ongoing and will be reported separately. Independent 
institutional review boards approved the study protocol 
and any amendments. Written informed consent was 
obtained from each participant. The study was registered 




Patients were eligible if they met the following 
criteria: previously untreated, operable, locally advanced, or 
inflammatory BC >2.0 cm in largest clinical diameter, and 
confirmed HER2 positivity (either immunohistochemistry 
3+ or 2+ and positive for fluorescent or chromogenic in 
situ hybridization). Patients were excluded from this study 
if they had impaired cardiac function (e.g., uncontrolled 
or symptomatic angina, clinically significant arrhythmias, 
congestive heart failure, transmural myocardial infarction), 
uncontrolled hypertension, concurrent treatment with 
therapies that can alter insulin levels (including chronic 
treatment with oral corticoids), metabolic disease (e.g., 
diabetes mellitus type I or II, obesity [BMI >30], impaired 
glucose tolerance [>128 mg/dL], hypercholesterolemia or 
hypertriglyceridemia of grade ≥3 according to CTC-NCIC 
version 4.0). See Supplementary Materials for additional 
inclusion and exclusion criteria.
Treatment
Chemotherapy consisted of weekly paclitaxel 
(80 mg/m2) for 12 weeks, concomitant trastuzumab (4 mg/kg 
loading dose followed by 2 mg/kg weekly for 12 weeks), 
followed by four courses of fluorouracil (600 mg/m2), 
epirubicin (75 mg/m2), and cyclophosphamide (600 mg/m2) 
(FE75C), administered every 3 weeks with concomitant 
trastuzumab (6 mg/kg). Corticosteroids and histamine-
receptor blockers were administered before paclitaxel. 
Patients on arm A received concomitant metformin 
(850 mg twice-daily) for 24 weeks, which was given in 
divided doses with meals, with gradual dose escalation to 
reduce gastrointestinal side effects. The starting dose was 
425 mg (one-half of a tablet) daily with dinner; dosage 
Table 5: Left ventricular ejection fraction (LVEF) in the mITT population
   Arm A Arm B
At baseline N = 38 N = 41
Median (IQR) 65.0% (58.0 to 69.3) 64.0% (61.0 to 68.5)
Week 12 N = 34 N = 40
Median change from baseline (IQR) –1.5% (–6.6 to 1.2) –1.0% (–6.8 to 4.0)
LVEF measurement (N, %) P = 0.032
No decrease or decrease <10%, still above LLN 32 (94.1%) 33 (82.5%)
Decrease <10%, below LLN 1 (2.9%) 1 (2.5%)
Decrease 10–15%, still above LLN 0 (0.0%) 6 (15.0%)
Decrease 10–15%, below LLN 0 (0.0%) 0 (0.0%)
Decrease >15%, still above LLN 1 (2.9%) 0 (0.0%)
  Decrease >15%, below LLN 0 (0.0%) 0 (0.0%)
End of treatment N = 32 N = 37
Median change from baseline (IQR) –4.0% (–6.0 to –1.8) –5.0% (–7.5 to –1.0)
LVEF measurement (N, %)
No decrease or decrease <10%, still above LLN 27 (84.4%) 30 (81.1%) P = 0.409
Decrease <10%, below LLN 1 (3.1%) 0 (0.0%)
Decrease 10–15%, still above LLN 2 (6.3%) 3 (8.1%)
Decrease 10–15%, below LLN 0 (0.0%) 3 (8.1%)
Decrease >15%, still above LLN 2 (6.3%) 1 (2.7%)
  Decrease >15%, below LLN 0 (0.0%) 0 (0.0%)
Data are median (IQR) or N (%) unless stated otherwise.  
LLN, lower limit of institutional normal; LVEF, left ventricular ejection fraction.
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increase was carried out in increments of 425 mg every 
week to a total of 850 mg twice-daily after 4 weeks. 
Patients had surgery within 4–5 weeks of the last cycle 
of neoadjuvant treatment. Post-surgery, patients received 
3-weekly trastuzumab to complete 1 year of neoadjuvant-
adjuvant therapy. Radiotherapy and endocrine therapy 
were according to local guidelines. 
Randomization and masking
Patients were randomly assigned (1:1 ratio) to arm 
A or arm B with a dynamic randomized block design and 
a minimization technique. Stratification factors were: age 
(<50 years vs ≥50 years); clinical tumor size (T2 [2–5 cm 
diameter] vs ≥T3 [>5 cm diameter]); clinical involvement 
of axillary lymph nodes (N0-1 vs ≥2); and hormone 
receptor (HR) status (estrogen receptor or progesterone-
receptor [PgR] positive; or both, vs estrogen-receptor and 
PgR negative). Two hundred and fifty-six randomization 
codes were generated with a block size of 16 patients (8 
per arm) per combined strata. On verification of patients’ 
eligibility, investigators were immediately notified of the 
allocated treatment.
Assessments
Grading of all adverse events (AEs) was made using 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE) version 4.0, and reported 
as cumulative incidence. Cardiac safety was monitored 
via incidence of significant asymptomatic left ventricular 
systolic dysfunction (LVSD), which was defined as ≥10% 
decline in left ventricular ejection fraction (LVEF) from 
baseline to <50% over the course of neoadjuvant treatment. 
LVEF was evaluated before study, after 12 weeks, and at 
the completion of treatment. Symptomatic LVSD was 
reported as a serious AE. Ink marks or surgical clips were 
used to mark the tumor bed before beginning neoadjuvant 
therapy, to facilitate surgical procedures and pathology. The 
Oracle Clinical® software tool was employed to assist with 
data management, data entry, and data validation. 
Analytical determination of circulating 
metformin in serum 
Serum was collected at the end of the 24-week 
intervention and stored at –80° C until assayed. Metformin 
concentrations were determined using high-performance 
liquid chromatography coupled to electrospray ionization 
and quadrupole time-of-flight mass spectrometry 
(HPLC-ESI-QTOF-MS). See Supplementary Materials for 
a detailed description of the analytical method. 
Sample size and statistical analysis
A Jung’s two-stage design for randomized phase II 
trials with a prospective control [73] was used to estimate 
the sample size. To keep the sample size small and the 
study period short, we employed a relatively large type 
I error (α = 15%) and a short-term outcome variable, the 
percentage of pCR as primary endpoint, which allowed for 
early termination of the study if the metformin containing 
arm failed to show efficacy at the interim analysis. The 
combination metformin plus chemotherapy/trastuzumab 
was considered worthwhile if a pCR ≥75% was obtained. 
By setting an α level of 0.15, a power of 0.80, a balanced 
allocation (1:1), and an expected drop-out rate of 25%, the 
sample size was 47 patients for arms A and B to ensure a per-
protocol (PP) assessment of pCR in 37 patients in each arm 
at the first stage. Only if at least two more patients achieved 
a pCR in the metformin-containing arm than in the reference 
arm, and provided no safety issues were identified, would 
the clinical trial proceed to the second stage. In such case, 
an additional recruitment of 65 patients for arms A and B (to 
ensure a PP assessment of pCR in 52 patients in each arm), 
will proceed. The metformin-containing arm was considered 
effective if 5 or more additional patients achieved a pCR in 
comparison with the reference arm at the end of the study 
(N = 224 patients at the planned final sample size).
The modified intention-to-treat (mITT)/safety 
population included all randomly assigned patients who 
received at least one dose of study medication. The PP/
efficacy population included all participants in the 
mITT population who had not violated any inclusion or 
exclusion criteria or deviated from the protocol in a way 
that could affect their efficacy assessments including 
sufficient treatment duration. 
Safety and efficacy parameters were evaluated 
descriptively. Categorical parameters are presented as 
frequencies (N, %) and were compared using a chi-
squared test (or Fisher’s exact test, when appropriate). 
Continuous variables are presented as mean ± standard 
deviation or median (1st/3rd quartile) and were compared 
using Student’s unpaired t-test or the Mann–Whitney 
U test when data were not normally distributed. Data 
normality before statistical analyses was assessed with 
the Kolmogorov-Smirnov test. Binary logistic regression 
was used to assess the prognostic effect of baseline 
characteristics on pCR. Unadjusted and adjusted odds 
ratios (ORs) with their relative 95% confidence intervals 
(CIs) were reported as a measure of association. After 84 
of 224 planned patients were randomized, the trial was 
closed early due to slow recruitment, which left the study 
underpowered relative to its primary endpoint (i.e., pCR). 
Therefore, the analyses presented here are considered 
exploratory and P values should not be used for drawing 
conclusions about the impact on pCR when adding 
neoadjuvant metformin to trastuzumab and chemotherapy. 
Statistical analyses were carried out using SPSS 
(IBM Corp. released 2016. IBM SPSS Statistics for 
Windows, Version 24.0; Armonk, NY) and STATA 
(StataCorp. 2013. Stata Statistical Software: Release 13; 
StataCorp LP, College Station, TX). 
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CONCLUSIONS
Larger studies are needed to determine if the 
similar high percentages of pCR observed in both 
treatment arms in the METTEN study reflects true lack 
of clinical efficacy of metformin or whether the study was 
underpowered for drawing conclusions about metformin 
effectiveness. Nevertheless, the METTEN study provides 
useful information, revealing that the addition of a 
conventional anti-diabetic dose of metformin to complex 
neoadjuvant regimens involving anthracycline/taxane-based 
chemotherapy and targeted therapies such as trastuzumab is 
well tolerated and safe. 
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